Literature DB >> 15364049

An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma.

David S Friedman1, M Roy Wilson, Jeffrey M Liebmann, Robert D Fechtner, Robert N Weinreb.   

Abstract

PURPOSE: To critically review the existing literature concerning risk factors for progression of ocular hypertension and glaucoma to assist in assigning levels of risk for individual patients.
DESIGN: Evidence-based review.
METHODS: A panel of physicians specializing in treatment of glaucoma patients was convened to critically analyze published population-based studies of ocular hypertension and glaucoma progression. The strength of evidence in support of reported risk factors was weighed.
RESULTS: Many putative risk factors for progression of ocular hypertension or glaucoma have been reported in the literature. The risk factors most strongly supported by evidence are higher intraocular pressure (IOP), greater cup-to-disk ratio, thinner central corneal measurement, and older age. Black race does not appear to be an independent risk factor, although black individuals tend to have thinner corneas, greater cup-to-disk ratios, and higher IOP, which increase their risk. The limited number of studies in which other suspected risk factors are reported prevents drawing firm conclusions about their importance at this time.
CONCLUSIONS: Only a subset of patients with ocular hypertension will eventually develop glaucoma. Decisions regarding the implementation and extent of therapy for ocular hypertension can be difficult and require an understanding of the relative importance of risk factors for progression. This review discusses the strength of evidence supporting reported risk factors and may be useful in assessing the risk for progression of individual patients.

Entities:  

Mesh:

Year:  2004        PMID: 15364049     DOI: 10.1016/j.ajo.2004.04.058

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  61 in total

1.  [Reliable recognition of glaucoma by spectral domain optical coherence tomography?].

Authors:  C K Brinkmann
Journal:  Ophthalmologe       Date:  2015-08       Impact factor: 1.059

2.  Biomarkers for glaucoma: from the lab to the clinic.

Authors:  N Von Thun Und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 3.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 4.  The future of glaucoma clinics.

Authors:  A M S Morley; I Murdoch
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

5.  Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.

Authors:  Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-16       Impact factor: 3.117

6.  Glaucoma medication adherence among African Americans: program development.

Authors:  Laura E Dreer; Christopher A Girkin; Lisa Campbell; Andy Wood; Liyan Gao; Cynthia Owsley
Journal:  Optom Vis Sci       Date:  2013-08       Impact factor: 1.973

7.  Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination.

Authors:  Eric Sellem; Jean François Rouland; Christophe Baudouin; Alain Bron; Philippe Denis; Jean-Philippe Nordmann; Jean Paul Renard
Journal:  BMC Ophthalmol       Date:  2010-03-26       Impact factor: 2.209

Review 8.  Circadian regulation in the retina: From molecules to network.

Authors:  Gladys Y-P Ko
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

9.  First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.

Authors:  Philippe Denis; Christophe Baudouin; Alain Bron; Jean-Philippe Nordmann; Jean Paul Renard; Jean François Rouland; Eric Sellem; Mourad Amrane
Journal:  BMC Ophthalmol       Date:  2010-02-24       Impact factor: 2.209

10.  Risk assessment for glaucoma.

Authors:  Robert N Weinreb; Felipe Medeiros
Journal:  Open Ophthalmol J       Date:  2009-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.